OGEN Oragenics Inc

0.0467 (1.64%)
After Hours
Last Updated: 16:00:00
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 1,439
Bid Price
Ask Price
News -
Day High 2.8866


52 Week Range


Day Low 2.75
Company Name Stock Ticker Symbol Market Type
Oragenics Inc OGEN AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0467 1.64% 2.8866 16:00:00
Open Price Low Price High Price Close Price Prev Close
2.75 2.75 2.8866 2.8866 2.8399
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
109 1,439 $ 2.84 $ 4,089 - 2.58 - 17.40
Last Trade Time Type Quantity Stock Price Currency
16:56:37 1 $ 2.86 USD

Oragenics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.33M - - - -240.29
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Oragenics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No OGEN Message Board. Create One! See More Posts on OGEN Message Board See More Message Board Posts

Historical OGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.003.182.752.903,955-0.1134-3.78%
1 Month2.833.6352.753.216,7230.05662.0%
3 Months3.294.482.653.5410,575-0.4034-12.26%
6 Months2.704.482.583.3210,5090.18666.91%
1 Year15.01217.402.589.35240,201-12.13-80.77%
3 Years32.928108.002.5848.383,881,418-30.04-91.23%
5 Years42.84224.402.5855.293,531,009-39.95-93.26%

Oragenics Description

Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.